NEW YORK (GenomeWeb News) – Trovagene today said it has licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia.
The San Diego-based molecular diagnostics firm holds the exclusive worldwide rights to an issued US patent, as well as patent applications in the US and elsewhere, covering NPM. It has licensed non-exclusive rights to the marker to several diagnostic and lab testing firms.
Under the agreement with Quest, Trovagene will receive upfront fees and royalty payments on an annual basis. Additional terms of the agreement were not disclosed.
"Physicians need accurate tools to assess prognosis, select therapies, and evaluate for bone marrow transplant," Trovagene Chief Technology Officer Charlie Rodi said in a statement. "Use of this marker can help physicians more effectively treat patients with AML."
Trovagene noted that many AMl patients have mutations in the NPM1 gene and testing for NPM1 mutations has been recommended by the National Comprehensive Cancer Network.